CURRENT LISTING OF CLAIMS

Claims 1-24 (cancelled).

25. (Currently amended) A conjugate comprising a Substance P analog and a polypeptide that inhibits protein synthesis, wherein the analog is selected from CYGGGGGGRPKPQQFF SarLMet([[O2]] $\underline{O_2}$)-amide (SEC ID NO:1) and CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

26. (Currently amended) The conjugate of claim 25, wherein said analog of Substance P ~~comprises the amino acid sequence~~ is CYGGGGGGRPKPQQFF SarLMet([[O2]] $\underline{O_2}$)-amide (SEQ ID NO:1).

27. (Currently amended) The conjugate of claim 25, wherein said analog of Substance P ~~comprises the amino acid sequence~~ is CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

28. (Currently amended) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P [[or]] analog ~~thereof~~ through a disulfide linkage.

29. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is saporin.

30. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.

31. (Previously Presented) The conjugate of claim 30, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.

32. (Previously Presented) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a toxin.

33. (Previously Presented) The conjugate of claim 32, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.

34. (Previously Presented) The conjugate of claim 32, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

35. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 25, and a pharmaceutically acceptable carrier.

36. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 29, and a pharmaceutically acceptable carrier.

Please add the following new claims.

37. (New) The conjugate of claim 31, wherein said ribosome-inactivation protein is ricin A chain.

38. (New) The conjugate of claim 31, wherein said ribosome-inactivation protein is gelonin.

39. (New) The conjugate of claim 31, wherein said ribosome-inactivation protein is pokeweed antiviral protein.

40. (New) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a chemical bond.

41. (New) A conjugate comprising a Substance P analog and a polypeptide that inhibits protein synthesis, wherein the analog comprises an amino acid sequence selected from CYGGGGGGRPKPQQFF SarLMet(O_2)-amide (SEQ ID NO:1) and CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

42. (New) The conjugate of claim 41, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGRPKPQQFF SarLMet(O_2)-amide (SEQ ID NO:1).

43. (New) The conjugate of claim 41, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

44. (New) The conjugate of claim 41, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a disulfide linkage.

45. (New) The conjugate of claim 41, wherein said polypeptide that inhibits protein synthesis is saporin.

46. (New) The conjugate of claim 41, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.

47. (New) The conjugate of claim 46, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.

48. (New) The conjugate of claim 47, wherein said ribosome-inactivation protein is ricin A chain.

49. (New) The conjugate of claim 47, wherein said ribosome-inactivation protein is gelonin.

50. (New) The conjugate of claim 47, wherein said ribosome-inactivation protein is pokeweed antiviral protein.

51. (New) The conjugate of claim 41, wherein said polypeptide that inhibits protein synthesis is a toxin.

52. (New) The conjugate of claim 51, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.

53. (New) The conjugate of claim 51, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

54. (New) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 41, and a pharmaceutically acceptable carrier.

55. (New) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 45, and a pharmaceutically acceptable carrier.

56. (New) he conjugate of claim 41, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a chemical bond.